Patents by Inventor Gwenaella Rescourio

Gwenaella Rescourio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210047344
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: March 4, 2019
    Publication date: February 18, 2021
    Applicant: AMGEN INC.
    Inventors: Gwenaella RESCOURIO, Ana GONZALEZ BUENROSTRO, Sean P. BROWN, Mike LIZARZABURU, Julio MEDINA, Salman Yojiro JABRI, Daqing SUN, Scott Preston SIMONOVICH, Xuelei YAN, Yihong LI, Yosup REW
  • Patent number: 10668067
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: June 2, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, John R. Butler, Benjamin Charles Milgram, Gwenaella Rescourio, Alessandro Boezio, Brian Andrew Sparling, Daniel La
  • Publication number: 20190167682
    Abstract: The present invention provides compounds of Formula (I), as defined in the specification, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders, cough, or itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Application
    Filed: July 20, 2017
    Publication date: June 6, 2019
    Applicant: AMGEN INC.
    Inventors: Matthew WEISS, John R. BUTLER, Benjamin Charles MILGRAM, Gwenaella RESCOURIO, Alessandro BOEZIO, Brian Andrew SPARLING, Daniel LA
  • Patent number: 9845305
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable dosage. Transdermal applications can be used.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: December 19, 2017
    Assignee: CORSAIR PHARMA, INC.
    Inventors: Cyrus K. Becker, Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
  • Publication number: 20170081303
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
    Type: Application
    Filed: October 18, 2016
    Publication date: March 23, 2017
    Inventors: Cyrus K. BECKER, Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
  • Patent number: 9505737
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: November 29, 2016
    Assignee: CORSAIR PHARMA, INC.
    Inventors: Cyrus K. Becker, Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
  • Publication number: 20160296497
    Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided
    Type: Application
    Filed: January 14, 2016
    Publication date: October 13, 2016
    Inventors: Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
  • Patent number: 9371264
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
    Type: Grant
    Filed: January 13, 2014
    Date of Patent: June 21, 2016
    Assignee: CORSAIR PHARMA, INC.
    Inventors: Cyrus K. Becker, Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
  • Patent number: 9320731
    Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.
    Type: Grant
    Filed: April 14, 2014
    Date of Patent: April 26, 2016
    Assignee: THERON PHARMACEUTICALS, INC.
    Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
  • Publication number: 20150166503
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
    Type: Application
    Filed: July 16, 2014
    Publication date: June 18, 2015
    Inventors: Cyrus K. BECKER, Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
  • Publication number: 20140256730
    Abstract: Compounds represented by formulae I, II, III, and IV including pro-drugs for treprostinil and prostacyclin analogs. Uses include treatment of pulmonary hypertension (PH) or pulmonary arterial hypertension (PAH). The structures of the compounds can be adapted to the particular application for a suitable treatment dosage. Transdermal applications can be used.
    Type: Application
    Filed: January 13, 2014
    Publication date: September 11, 2014
    Applicant: Corsair Pharma, Inc.
    Inventors: Cyrus K. BECKER, Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
  • Publication number: 20140249195
    Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided
    Type: Application
    Filed: April 14, 2014
    Publication date: September 4, 2014
    Applicant: THERON PHARMACEUTICALS, INC
    Inventors: Jürg R. PFISTER, Gwenaella RESCOURIO, Meenakshi S. VENKATRAMAN, Xiaoming ZHANG
  • Patent number: 8742134
    Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.
    Type: Grant
    Filed: December 20, 2012
    Date of Patent: June 3, 2014
    Assignee: Theron Pharmaceuticals, Inc.
    Inventors: Jurg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
  • Patent number: 8742131
    Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetyl-choline receptor-mediated diseases, such as pulmonary diseases, are provided.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: June 3, 2014
    Assignee: Theron Pharmaceuticals, Inc.
    Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
  • Patent number: 8426611
    Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: April 23, 2013
    Assignee: Theron Pharmaceuticals Inc.
    Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
  • Publication number: 20130059898
    Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetyl-choline receptor-mediated diseases, such as pulmonary diseases, are provided.
    Type: Application
    Filed: January 27, 2011
    Publication date: March 7, 2013
    Applicant: Theron Pharmaceuticals, Inc.
    Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
  • Publication number: 20120029044
    Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetylcholine receptor-mediated diseases, such as pulmonary diseases, are provided.
    Type: Application
    Filed: January 27, 2011
    Publication date: February 2, 2012
    Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang